ArticleJournal of translational medicine2026
Spatial distribution analysis of tertiary lymphoid structures in esophageal squamous cell carcinoma predicts patient survival and response to neoadjuvant chemo-immunotherapy.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tertiary lymphoid structures in neoadjuvant and perioperative cancer immunotherapy: a review and proposed framework for biomarker interpretation and validation.Frontiers in immunology · 2026Review
- Immunosuppressive tumor microenvironment and immunotherapy resistance of esophageal carcinoma.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic and predictive significance of tertiary lymphoid structures (TLSs) exhibits spatial specificity in various cancers. However, the spatial distribution, phenotypic characteristics of TLSs in esophageal squamous cell carcinoma (ESCC) and their impact on prognosis and prediction are not yet fully understood.
methodsWe performed multiplex immunofluorescence staining and digital image analysis on 87 untreated ESCC specimens to characterized TLSs expression and phenotypic characteristics, CD8 + T cells and PNAD+ high endothelial venules (HEVs) in different spatial regions of ESCC tissues using Panel-1 (CD20/CD21/CD23/ PNAD/CD8/Pan CK/DAPI). Panel-2 (CD20/CD3/Foxp3/DC-LAMP/Pan CK/DAPI) was used to evaluate the spatial distribution of TLS-related immune cells (CD20 + B cells, CD3 + T cells, Foxp3 + Treg cells, and LAMP+ mature DCs) within the tumor microenvironment of ESCC. Furthermore, the predictive value of TLSs and the clinical prognostic significance of TLSs at different spatial locations were assessed in an independent cohort of 15 ESCC patients who received neoadjuvant chemo- immunotherapy (NACI).
resultsIn untreated ESCC, a high number/density of mature follicular TLSs (F-TLSs) in the stromal distal region (> 500 μm from the outer boundary of the tumour nests) was significantly associated with better overall survival (OS) in patients (number: p = 0.0092; density: p = 0.0268). Patients with distal high F-TLSs not only exhibited high densities of CD3 + T cells, CD8 + T cells, CD20 + B cells, LAMP + DCs, and PNAD+HEVs in the stromal regions, but this was also associated with increased CD8 + T cell infiltration within the tumour nests (p < 0.05). Additionally, it was correlated with a lower levels of Foxp3 + Treg cells in the stromal distal and tumour nests regions. In the NACI cohort, the total amount of TLSs significantly increased after treatment. The partial response (PR) group exhibited higher numbers and densities of F-TLSs post-treatment than the non-PR group (p < 0.05). High numbers/densities of total TLSs, early-TLSs, and F-TLSs in the stromal proximal region (≤ 500 μm from the outer boundary of the tumour nests) of post-treatment specimens were significantly associated with better OS (p < 0.05).
conclusionsOur research establishes that the prognostic value of TLSs is contingent upon their spatial location and maturation status. In untreated ESCC, distal mature F-TLSs is critical prognostic indicator; however, after NACI, TLSs quantity and spatial distribution were reshaped. Mature F-TLSs predicted treatment response, while treatment-induced expansion of TLSs localised at the proximal tumour-stroma interface is a key indicator for predicting favourable long-term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.